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Inhibition of Angiogenesis by Interleukin-4 Gene Therapy in
Rat Adjuvant-Induced Arthritis
Christian S. Haas,1 M. Asif Amin,1 Brittany B. Allen,1 Jeffrey H. Ruth,1
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Objective. Interleukin-4 (IL-4) can modulate neo-
vascularization. In this study, we used a gene therapy
approach to investigate the role of IL-4 in angiogenesis
in rat adjuvant-induced arthritis (AIA), a model for
rheumatoid arthritis.
Methods. Rats received an adenovirus producing
IL-4 (AxCAIL-4), a control virus without insert, or
control vehicle (phosphate buffered saline) intraarticu-
larly before arthritis onset. At peak onset of arthritis,
rats were killed. Vascularization was determined in the
synovial tissue, and correlations with inflammation
were assessed. Ankle homogenates were used in angio-
genesis assays in vitro and in vivo, and protein levels of
cytokines and growth factors were assessed by enzyme-
linked immunosorbent assay. Synovial tissue expres-
sion of v integrins was determined by immunohisto-
chemistry.
Results. IL-4 induced a reduction in synovial
tissue vessel density, which was paralleled by a decrease
in inflammation. AxCAIL-4 joint homogenates signifi-
cantly (P < 0.05) inhibited both endothelial cell (EC)
migration and tube formation in vitro. Similarly,
AxCAIL-4 inhibited capillary sprouting in the rat aortic
ring assay, and vessel growth in the in vivo Matrigel
plug assay. The angiostatic effect occurred despite high
levels of vascular endothelial growth factor (VEGF), and
was associated with down-regulation of the proangio-
genic cytokines IL-18, CXCL16, and CXCL5 and up-
regulation of the angiogenesis inhibitor endostatin. Of
interest, AxCAIL-4 also resulted in decreased EC ex-
pression of the v and 3 integrin chains.
Conclusion. In rat AIA, IL-4 reduces synovial
tissue vascularization via angiostatic effects, mediates
inhibition of angiogenesis via an association with al-
tered pro- and antiangiogenic cytokines, and may in-
hibit VEGF-mediated angiogenesis and exert its angio-
static role in part via v3 integrin. This knowledge of
the specific angiostatic effects of IL-4 may help optimize
target-oriented treatment of inflammatory arthritis.
Interleukin-4 (IL-4), a pleiotropic cytokine and
crucial modulator of the immune system (1), has been
implicated in neovascularization (2–4). However, its
specific role and mechanisms in the context of angiogen-
esis remain unclear. IL-4 has been demonstrated to have
inhibitory effects on the critical steps of angiogenesis in
vitro (3), a role that has been supported by in vivo
studies showing that tumors expressing IL-4 have re-
duced vascularity (4). Similarly, we have shown that IL-4
blocks induction of basic fibroblast growth factor
(bFGF)–mediated corneal neovascularization in rats (2).
In contrast, other studies have shown that IL-4 may in-
duce angiogenesis in vitro and in vivo (5,6). Of note, the
pro- or antiangiogenic role may be dose-dependent (2).
Inflammatory synovitis is a hallmark feature of
rheumatoid arthritis (RA) and strongly associated with
neovascularization in the synovial tissue (7). The process
of neovascularization is of pivotal importance in the
progression of the disease, by creating a direct conduit
for the influx of inflammatory cells and thereby exacer-
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bating the inflammatory response (8). Thus, targeting
neovascularization is an interesting and promising ap-
proach for the treatment of RA.
IL-4 cannot be detected in the serum or synovial
fluid of RA patients (9,10), while studies in animal
models of arthritis have yielded conflicting results
(11,12). For example, administration of IL-4 amelio-
rated the course of murine streptococcal cell wall–
induced arthritis (13) and significantly reduced disease
incidence and severity in murine collagen-induced ar-
thritis (CIA) (14). In contrast, Lubberts et al noted
enhanced onset and aggravation of synovial inflamma-
tion following IL-4 treatment in CIA (15), and in a
recent study using the K/BxN model, IL-4 promoted
arthritis (11). We recently demonstrated that IL-4, pre-
ventatively delivered by adenoviral gene therapy, im-
proved arthritis and attenuated inflammation and vas-
cularization of the synovium in rat adjuvant-induced
arthritis (AIA) (12). Our experiments revealed a dra-
matic clinical improvement following preventative ad-
ministration of IL-4; nevertheless, the treatment failed
to lower levels of crucial proinflammatory cytokines,
such as tumor necrosis factor  (TNF) or IL-1,
suggesting that modulation of other factors may be
occurring.
Important mediators of angiogenesis include in-
tegrins, which are transmembrane glycoproteins consist-
ing of 2 non–covalently bound - and -chains (16).
Integrins v3 and v5 can clearly modulate angiogen-
esis and have become a focus in strategies aimed at
modifying neovascularization (16). In a rabbit model of
arthritis, injection of an v3 antagonist not only inhib-
ited angiogenesis but also attenuated disease manifesta-
tions (17). Of note, expression of v integrin can be
modified by cytokines, including IL-4 (18).
In this study, we show that reduced synovial tissue
vascularization in rat AIA in response to preventative
IL-4 gene therapy could be attributed to inhibition of
angiogenesis. This effect was associated with a signifi-
cant shift in the balance of pro- and antiangiogenic
factors in vivo, but also could be mediated directly
via IL-4. We also provide evidence that the angiostatic
response may be mediated, in part, by altered expression
of v3 integrin.
MATERIALS AND METHODS
Preparation, propagation, purification, and titering of
adenoviruses. Replication incompetent adenoviruses that pro-
duce rat IL-4 (AxCAIL-4) or having no foreign gene insert
(AxCANI) were prepared via homologous recombination in
293 cells, as described previously (12). In brief, expression of
the rat IL-4 gene was directed by the chicken -actin promoter
and the cytomegalovirus enhancer of pAxCAwt, a 45-kb cos-
mid containing the full-length sequence of type 5 adenovirus
deleted of the E1A, E1B, and E3 regions (19,20). Viruses were
propagated in 293 cells, purified, and titered as described
previously (21).
Induction of rat AIA, experimental setup, and tissue
sampling. Female Lewis rats (weight 100 grams) were injected
subcutaneously with 300 l (5 mg/ml) lyophilized Mycobac-
terium butyricum (Difco, Detroit, MI) in sterile mineral oil,
administered at the base of the tail on day 0. Rats were divided
into 3 groups, comprising an AxCAIL-4 group as well as 2
control groups, one designed to receive phosphate buffered
saline (PBS) and the other to receive AxCANI (virus without
insert); the latter group was included to distinguish between
the adenoviral and IL-4–mediated effects, since use of adeno-
viruses in animal models of arthritis has been shown to result
in increased inflammation (12,15). In this preventative treat-
ment design, 5  108 plaque-forming units of AxCAIL-4 or
AxCANI, or PBS, was administered intraarticularly into each
ankle on day 8 postinduction, prior to development of arthritis.
All animals were killed at day 18 after adjuvant injection, at the
time of maximal inflammation, and rat joints were collected for
further examination.
Ankle homogenates and protein extracts. For enzyme-
linked immunosorbent assays (ELISAs) and angiogenesis
assays, rat joints were skinned, weighed, and frozen at 80°C.
Ankles were homogenized as described previously (12), and
the concentration of protein in each lysate was determined
by using a bicinchoninic acid assay (Pierce, Rockford, IL).
Hemoglobin content was determined by the tetramethylbenzi-
dine (TMB) method, and compared with a standard curve.
Cell culture. Human dermal microvascular endothelial
cells (HMVECs) (Cambrex, Walkersville, MD) were main-
tained in growth factor–complete endothelial cell (EC) basal
medium (EBM) supplemented with 10% fetal bovine serum
(FBS) and additional growth factors. Cells were maintained at
37°C in 5% CO2 and used between passages 5 and 12.
HMVEC chemotaxis assay. HMVEC chemotaxis was
performed using a 48-well Boyden chemotaxis chamber
(Neuroprobe, Cabin John, MD) as described previously (22).
HMVECs (4  104 cells/well in EBM  0.1% FBS) were
plated in the bottom wells of the chambers with a
polyvinylpyrrolidone-free polycarbonate filter (8 m pore size;
Nucleopore, Pleasant, CA). Chambers were inverted and
incubated at 37°C in 5% CO2 for 2 hours, which allowed
HMVECs to attach to the membrane. The chambers were
inverted again, and pooled joint homogenates from 5 rat
ankles per group (60 g protein per ml) or PBS or positive
control bFGF (60 nM) were added. The chambers were
incubated at 37°C for 2 hours. To determine the role of
proangiogenic factors in rat AIA joints upon HMVEC migra-
tion, pooled homogenates of AxCANI-treated ankle joints
were preincubated (37°C for 60 minutes) with neutralizing goat
anti–IL-18 or goat anti-CXCL16 antibodies (10 g/ml; R&D
Systems, Minneapolis, MN), prior to being used as stimulants.
AxCANI and AxCAIL-4 homogenates preincubated with goat
IgG served as controls. Chemotaxis was performed in quadru-
plicate, with results expressed as the number of migrated
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HMVECs per 3 high-power fields (hpf) (at 400 magnifica-
tion). Each assay was repeated at least 3 times.
In vitro capillary morphogenesis assay. Assessment of
tube formation by HMVECs in growth factor–reduced (GFR)
Matrigel was used to evaluate the effect of AxCAIL-4 rat joint
homogenates on capillary morphogenesis, as described previ-
ously (23). HMVECs were suspended in EBM with 1% FBS
and seeded in Labtek chamber slides on GFR Matrigel (Bec-
ton Dickinson, Bedford, MA) at a density of 1.6  104 cells per
chamber. Immediately after plating, pooled rat joint homoge-
nates (from 5 rat ankles per group; 60 g protein per ml)
from the AxCAIL-4–, AxCANI-, and PBS-treated groups,
phorbol myristate acetate (PMA) (50 nM) as positive control,
or DMSO in place of PMA as vehicle control were added to
the cell suspension. After 16–18 hours of incubation at 37°C in
5% CO2, capillary morphogenesis was examined under a
phase-contrast microscope. Node formation (defined as a
nodular contact formation of at least 3 adherent EC tubes) was
determined in a blinded manner, and the number of circular
tube network formations was evaluated. Similarly, EC tube
formation in response to AxCAIL-4 was determined in the
presence of neutralizing antibodies to rat IL-4 (BD PharMin-
gen, San Diego, CA), human CXCL16, and human IL-18
(R&D Systems). Each assay was performed 3 times.
Rat aortic ring sprouting growth assay. Aortas were
removed from female Sprague-Dawley rats (weight 200
grams), cleaned of surrounding connective tissue, and sliced
into 1-mm–thick rings (24). Aortic rings were then placed into
300 l of Matrigel in 48-well plates. Serum-free EBM (300 l)
containing rat joint homogenates from 8 rats per group (60 g
protein per ml) was added. Basic FGF (100 nM) and PMA
(50 nM) were used as positive controls, while PBS and DMSO
served as negative vector controls. Aortic rings were incubated
at 37°C in 5% CO2 to allow microvessel sprouting from the
adventitial layer. Sprouting was measured using the following
scale: 0  no sprouting; 1  migrated cells without sprouting;
2  isolated sprouting; 3  sprouting in 25–50% of the arterial
ring circumference; 4  sprouting in 50–75% of the circum-
ference; and 5  sprouting in 75–100% of the circumference.
Matrigel plug in vivo angiogenesis assay. To examine
the effects of AxCAIL-4 treatment on angiogenesis in vivo,
Matrigel plug assays were performed as described previously
(25). C57BL/6 mice (10–11 mice per group; NCI, Bethesda,
MD) were anesthetized by isofluorane inhalation (Abbott
Pharmaceuticals, Abbott Park, IL), shaved on the ventral aspect,
and given a subcutaneous injection of GFR Matrigel (500 l/
injection) containing pooled rat joint homogenates (from 5
rats) at a final concentration of 120 g protein per ml. Matrigel
containing PBS or bFGF (1 ng/ml) served as a negative and
positive control, respectively. After 7 days, plugs were dis-
sected and homogenized, and hemoglobin content was deter-
mined as described above.
ELISAs. Six-to-eight ankle homogenates were analyzed
using commercially available ELISA kits for the following
rat cytokines and growth factors: cytokine-induced neutrophil
chemoattractant 1 (CINC-1)/CXCL1, lipopolysaccharide-
induced CXC chemokine (LIX/CXCL5), IL-6, IL-13, IL-18,
transforming growth factor  (TGF), vascular endothelial
growth factor (VEGF), and endostatin. ELISAs were per-
formed according to the manufacturer’s protocol. CXCL16
levels were measured by coating 96-well polystyrene plates
with rabbit anti-human CXCL16 (PeproTech, Rocky Hill, NJ),
followed by a blocking step as described previously (26).
Biotinylated rabbit anti-human antibody (PeproTech) was used
to detect CXCL16 with the streptavidin–peroxidase method
(BD PharMingen) and TMB as color substrate (Sigma, St.
Louis, MO). All samples were analyzed in duplicate.
Immunohistochemistry. Immunohistochemistry was
performed on 8 m synovial tissue rat AIA cryosections (3–5
rats per group) for the EC marker von Willebrand factor (vWF)
(DakoCytomation, Carpinteria, CA) and the integrin chains v,
3, and 5 (rabbit anti-rat antibodies; Santa Cruz Biotechnology,
Santa Cruz, CA). Isotype-matched nonspecific IgG was used as a
negative control. Immunostaining was performed using Vector
Elite ABC Kits (Vector, Burlingame, CA) and diaminobenzidine
(Kirkegaard & Perry, Gaithersburg, MD) as a chromogen, fol-
lowed by counterstaining with hematoxylin.
Microscopic analysis. Various synovial tissue cell types
were evaluated for positive staining, and included lining cells,
mononuclear cells (MNCs), ECs, and smooth muscle cells
(SMCs). Immunostaining was evaluated and graded by a
pathologist (GKH III) in a blinded manner, as described
previously (27). Cell types were distinguished on the basis of
their morphologic characteristics and/or immunohistochemical
staining reaction, as previously described (26,28). Each syno-
vial tissue component was graded using a frequency of staining
scale, ranging 0–100%, in which 0% indicates no staining and
100% indicates that all cells are immunoreactive. The percent-
age of reactivity was calculated as the number of cells of a
given type reacting with a specific antibody divided by the total
number of cells of that given type. Synovial tissue vascularity
was scored on a scale of 1–4, as follows: 1  marked decrease
in vessels; 2  normal density in vessels; 3  increased density
in vessels; and 4  marked increase in vessel density, resem-
bling granulation tissue. In addition, an inflammation score
was obtained using the following scoring system: 1  normal;
2  increased number of inflammatory cells, arrayed as
individual cells; 3  increased number of inflammatory cells,
including distinct clusters (aggregates); and 4  marked dif-
fuse infiltrate of inflammatory cells. Score data were pooled
and expressed as the mean  SEM of each data group.
Statistical analysis. All values are presented as the
mean  SEM. Since rats received identical injections in each
ankle based on their group assignment, and rats with AIA
often developed inflammation to different degrees in each of
the hind limbs, each ankle was assessed independently for
statistical purposes (12). Statistical analysis was performed
using Student’s t-test, with a P value less than 0.05 considered
statistically significant. Pearson’s correlation coefficients were
assessed to describe the relationship between vascularity score
and synovial tissue inflammation.
RESULTS
IL-4–mediated decrease in synovial vasculariza-
tion paralleled by reduction in inflammation. To study
the effect of IL-4 gene therapy on vascularization in the
context of inflammatory changes, vessel density was
assessed and correlated with the extent of histologic
inflammation. Injection of rat ankle joints with AxCANI
was associated with an increase in vascularity score,
which was significantly reduced by treatment with
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AxCAIL-4, even when compared with the PBS group,
suggesting that IL-4 has possible antiangiogenic proper-
ties (Figure 1A). Immunostaining with vWF (an EC
marker) confirmed decreased vessel density in the
AxCAIL-4–treated group (Figure 1D). Of interest, syno-
vial inflammation paralleled the vascularization in the 3
groups, and the inflammation score was significantly
reduced in the AxCAIL-4–treated rats compared with
the PBS or AxCANI group (Figure 1B). In fact, the
vascularity score in all groups was strongly correlated
with the extent of inflammation in the rat AIA joints
(r  0.77, P  0.05; n  18) (Figure 1C).
Significant in vitro inhibition of EC migration by
IL-4 gene delivery. To determine whether the increased
vascularization in rat AIA joints might be due to an
increase in proangiogenic factors, we first tested EC
chemotaxis in vitro in response to joint homogenates
from PBS-treated animals. The HMVEC migratory re-
Figure 1. Reduction of synovial neovascularization in rat adjuvant-induced arthritis (AIA) ankle joints by intraarticular injection of interleukin-
4–producing adenovirus (AxCAIL-4). A, The histologic vascularity score (range 1–4) was determined by assessing the vessel density in the synovial
tissue from AxCAIL-4–treated rats with AIA as compared with the group receiving control virus without insert (AxCANI) or phosphate buffered
saline (PBS)–treated rats. B, The histologic inflammation score (scale 1–4) was assessed by determining the presence of inflammatory cells in the
synovium from each group. Bars show the mean and SEM. C, The vascularity score of all groups (n  18) strongly correlated with the extent of
inflammation in the rat joints. D, Photographs of representative immunohistologic findings for the endothelial cell marker von Willebrand factor,
showing reduced synovial vascularity in the AxCAIL-4–treated animals compared with AxCANI-treated synovial tissue (original magnification  200).
Color figure can be viewed in the online issue, which is available at http://www.arthritisrheum.org.
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sponse was 2-fold higher than baseline values and
comparable with the effects of bFGF (Figure 2A).
To assess whether the reduction of functional
blood vessels in response to IL-4 was due to an angio-
static effect, we further studied EC chemotaxis in vitro in
response to joint homogenates from AxCAIL-4– and
Figure 2. Decrease in rat AIA joint homogenate–induced endothelial cell migration and tube formation in vitro by AxCAIL-4 treatment, as assessed
by chemotaxis assay, in vitro capillary morphogenesis assay, and in vitro Matrigel assay using human dermal microvascular endothelial cells
(HMVECs) and rat AIA joint homogenates as stimulant. Each assay was performed in triplicate, with results expressed as the mean and SEM of
independent experiments. n  number of experiments per group. A, In vitro migration of HMVECs in response to joint homogenates (60 g
protein/ml) from each treatment group of rats with AIA compared with PBS as negative stimulant control (PBScon) and basic fibroblast growth
factor (bFGF) (60 nM) as positive control. B and C, Endothelial cell tube formation in Matrigel, expressed as the number of nodular tube contacts
(B) or circular tube structures (C) per high-power field (hpf). DMSO served as vehicle control, and phorbol myristate acetate (PMA) as positive
control. D, Photographs of representative assay findings in each group (original magnification  200). Color figure can be viewed in the online issue,
which is available at http://www.arthritisrheum.org. See Figure 1 for other definitions.
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AxCANI-treated ankles (Figure 2A). Whereas HMVEC
migration in response to AxCANI joint homogenates
was comparable with that in the PBS-treated group
(mean  SEM 96  7 versus 104  4 cells/3 hpf), the
migratory response was almost completely inhibited by
AxCAIL-4 (59  6 cells/3 hpf; P  0.05), suggesting that
IL-4 gene delivery inhibits EC migration, a critical step
in the process of neovascularization.
Reduction of EC tube formation by IL-4 gene
delivery in the in vitro capillary morphogenesis assay.
To elucidate the role of IL-4 gene therapy in another
important step of angiogenesis, namely EC differentia-
tion, we studied in vitro EC tube formation in response
to PBS, AxCANI, and AxCAIL-4 joint homogenates
(Figures 2B, C, and D). Homogenates from PBS- and
AxCANI-treated rats with AIA stimulated tube forma-
tion. However, AxCAIL-4 treatment resulted in a joint
environment that significantly inhibited EC tube forma-
tion (P  0.05). These results imply that IL-4 gene
delivery attenuates EC differentiation.
Inhibition of rat AIA joint homogenate–induced
vessel sprouting by AxCAIL-4 in the rat aortic ring
assay. To validate our findings of an inhibitory effect of
IL-4 on vessel formation, we tested both EC migration
and EC differentiation in the rat aortic ring assay, and
examined whether homogenates of AxCAIL-4–treated
rat AIA ankle joints were less likely to promote EC
sprout formation compared with homogenates derived
from the other 2 groups (Figure 3). Sprouting started
after 10 days in the PBS group and showed a constant
increase until day 28, thus confirming that rat AIA joint
homogenates have proangiogenic properties. AxCANI
therapy resulted in similar sprout formation. In contrast,
aortic rings treated with AxCAIL-4 joint homogenates
did not develop any appreciable sprouting (Figures 3A
and B; representative images shown in Figure 3C).
Inhibition of rat AIA joint homogenate–induced
angiogenesis in vivo by AxCAIL-4. To test the angio-
static response to IL-4 gene delivery in an in vivo setting,
we performed a Matrigel plug in vivo angiogenesis assay.
GFR Matrigel containing rat joint homogenates treated
with PBS, AxCANI, or AxCAIL-4 were injected subcu-
taneously into C57BL/6 mice and analyzed after 7 days
(Figure 4A). Hemoglobin measurements, as a marker of
blood vessel penetration, showed that AIA joint homog-
enates treated with PBS induced blood vessel formation
as compared with the effects of PBS as negative stimu-
lant control (PBScon in Figure 4A) (P  0.05). Joint
homogenates from the AxCANI-treated group did not
alter hemoglobin content, suggesting that neovascular-
ization was unaffected by the control vector, whereas
IL-4 gene delivery resulted in a significant inhibition of
blood vessel growth (P  0.05), showing that AxCAIL-4
impairs the proangiogenic environment in rat AIA joints.
To confirm these findings, we determined
whether IL-4 gene delivery could reduce vascularity
(which is proportional to hemoglobin content) in the rat
AIA joints. Hemoglobin levels, as measured in the ankle
homogenates, increased in response to AxCANI treat-
Figure 3. Inhibition of rat AIA joint homogenate–induced vessel
sprouting by AxCAIL-4 in the rat aortic ring assay. After placement in
growth factor–reduced Matrigel and covering with medium plus rat
joint homogenates (at 60 g/ml protein), aortic rings were observed
for vessel sprouting using a scale of 0–5. A, Sprout formation score
over time in the 3 treatment groups (n  8 joint homogenates per
group). B, Sprout formation score at day 28 in response to treated rat
AIA joint homogenates compared with phorbol myristate acetate
(PMA)–induced sprouting and compared with DMSO vehicle con-
trol. Bars show the mean and SEM. C, Photographs of representative
aortic ring sprouting in each group (original magnification  200).
Color figure can be viewed in the online issue, which is available at
http://www.arthritisrheum.org. See Figure 1 for other definitions.
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ment, but were significantly reduced in the AxCAIL-4–
treated group when compared with the PBS- and
AxCANI-treated groups (P  0.05) (Figure 4B). Thus,
these findings corroborate the observation of IL-4 as an
angiostatic cytokine in vivo.
Change in expression of pro- and antiangiogenic
mediators using preventative IL-4 gene therapy. To
determine whether the angiostatic effects of IL-4 gene
delivery were mediated via pro- and antiangiogenic
factors, we studied protein expression of select cyto-
kines, chemokines, and growth factors in the rat AIA
joint homogenates (Table 1). IL-18 and CXCL16, both
of which are cytokines with strong proangiogenic prop-
erties (23,29), were significantly down-regulated follow-
ing IL-4 gene therapy, whereas the angiogenesis inhibi-
tor endostatin showed up-regulation in the AxCAIL-4–
treated group compared with AxCANI-treated animals
(mean  SEM 1,550  266 versus 405  124 pg/mg
protein; P  0.05). In addition, expression of LIX/CXCL5,
the rat homolog of epithelial-derived neutrophil attract-
ant 78 (ENA-78)/CXCL5, was strongly down-regulated
by AxCAIL-4, implying that this chemokine may con-
tribute to mediating the proangiogenic effects. Similarly,
levels of CINC-1/CXCL1, the rat homolog of growth-
related oncogene  (GRO)/CXCL1, were significantly
lower in the AxCAIL-4 group. Expression of IL-6,
Figure 4. Inhibition of rat adjuvant-induced arthritis (AIA) joint homogenate–induced angiogenesis in vivo
mediated directly or indirectly by interleukin-4 (IL-4)–producing adenovirus (AxCAIL-4). A, Assessment of
blood vessel growth, reflected in hemoglobin content, in response to treated rat AIA joint homogenates, using
Matrigel plugs with test substance injected into C57BL/6 mice; phosphate buffered saline (PBS) served as
negative stimulant control (PBScon) and basic fibroblast growth factor (bFGF) (1 ng/ml) as positive control. n
 number of mice. B, Hemoglobin content as an indirect marker for neovascularization in rat joint homogenates,
emphasizing the angiostatic effect of IL-4 in vivo. n  number of joint homogenates. C, Human dermal
microvascular endothelial cell (HMVEC) migration in response to tissue homogenates from rats with AIA
treated with control virus without insert (AxCANI) in the presence or absence of neutralizing antibodies. IgG
served as control. n  number of assays. D, Effects of neutralizing antibodies on AxCAIL-4–induced endothelial
tube formation on Matrigel in vitro. IgG served as control. n  number of assays. Bars show the mean and SEM.
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known to have a proinflammatory role in RA and,
possibly, proangiogenic properties (30), was not altered
by IL-4 gene delivery, nor was there any effect of
AxCAIL-4, when compared with AxCANI, on IL-13, an
antiinflammatory cytokine in RA with a dual role in
angiogenesis. Surprisingly, VEGF was slightly but signif-
icantly up-regulated in rat joints following IL-4 treat-
ment. Expression of TGF, known to be a bifunctional
regulator of angiogenesis, was also increased by IL-4
gene delivery.
Inhibition of in vitro EC migration by blocking
of the proangiogenic cytokines IL-18 and CXCL16. To
test whether the observed reduction in proangiogenic
factors in response to AxCAIL-4 may explain the angio-
static effects in this study, we studied EC chemotaxis in
response to AxCANI joint homogenates following pre-
incubation with neutralizing antibodies (Figure 4C).
HMVEC migration was significantly reduced in the
presence of anti–IL-18 or anti-CXCL16 antibodies
(mean  SEM 43  6% and 55  7%, respectively,
versus 100% in the AxCANI  IgG group; P  0.05) and
comparable with the reduction in HMVEC migration in
response to AxCAIL-4 homogenates, in which IL-18 and
CXCL16 levels were low, suggesting a direct proangio-
genic role of IL-18 and CXCL16 in this setting.
Direct antiangiogenic effects of IL-4. Using the
in vitro Matrigel assay, we further tested whether the
antiangiogenic effects of IL-4 could be mediated di-
rectly, rather than indirectly, by altering expression of
other cytokines. Blocking of IL-4 using neutralizing
antibodies reversed the AxCAIL-4–mediated inhibition
of EC tube formation, whereas this was not observed in
the presence of control IgG or antibodies against IL-18
or CXCL16. These results indicate that in addition to
reducing the expression of proangiogenic cytokines, IL-4
can also exert a direct effect on target ECs to decrease
angiogenesis.
Down-regulation of v integrins on ECs in re-
sponse to AxCAIL-4 gene therapy. To determine the in
vivo effect of IL-4 on the expression of the v3 and
v5 integrins, immunohistochemistry was performed
(Figure 5). The integrin v chain was highly expressed
on ECs in PBS-treated rat AIA synovium (mean  SEM
76.0  6.8%), but was significantly down-regulated by
IL-4 (18.3  7.3%; P  0.05). Surprisingly, in response
to IL-4, v integrin expression was increased on synovial
MNCs and SMCs (P  0.05), and tended to be higher on
lining cells (Figure 5A). Integrin 3 up-regulation on
ECs was completely reversed by IL-4 gene delivery (P 
0.05). In addition, AxCAIL-4 increased integrin 3
expression on MNCs and lining cells (P  0.05) (Figure
5B). In contrast, synovial expression of the integrin 5
chain was not significantly altered by IL-4 gene delivery
(Figure 5C), suggesting that IL-4 exerts its antiangio-
genic effects via integrin v3, but not v5.
DISCUSSION
RA is characterized by progressive destruction of
the joints, associated with unchecked cellular influx and
angiogenesis in the synovial tissue. Proinflammatory
cytokines, such as IL-1 and TNF, have been shown to
be pivotal in the pathogenesis and progression of the
disease and have been successfully targeted in the treat-
Table 1. Pro- and antiangiogenic factors in rat adjuvant-induced arthritis ankle homogenates among the preventatively
injected AxCAIL-4, AxCANI, and PBS groups*
Factor, pg/mg protein PBS AxCANI AxCAIL-4
CXCL16 201.0  17.6 (n  6) 242.1  29.7 (n  7) 132.3  20.4 (n  7)†
CINC-1 99.4  26.1 (n  8) 169.0  16.1 (n  7) 6.3  3.2 (n  6)†
LIX 1,296  465 (n  8) 2,759  229 (n  7) 180  24 (n  6)‡
IL-18 276.4  23.2 (n  7) 332.5  33.9 (n  6) 162.3  14.4 (n  8)†
IL-13 66.5  12.8 (n  8) 32.2  4.7 (n  6) 31.6  3.6 (n  7)§
IL-6 80.1  33.6 (n  8) 49  16.1 (n  8) 57.2  22.5 (n  8)
VEGF 35.3  3.8 (n  7) 36.2  1.2 (n  6) 54.1  5.1 (n  6)†
Endostatin 1,678  388 (n  7) 405  124 (n  7) 1,550  266 (n  8)‡
TGF 673  64 (n  7) 499  55 (n  6) 952  79 (n  8)†
* Values are the mean  SEM of the indicated chemokine, cytokine, or growth factor in the phosphate buffered saline (PBS)
group and the groups receiving interleukin-4 (IL-4)–producing adenovirus (AxCAIL-4) or control virus without insert
(AxCANI). CINC-1  cytokine-induced neutrophil chemoattractant 1; LIX  lipopolysaccharide-induced CXC chemokine;
VEGF  vascular endothelial growth factor; TGF  transforming growth factor .
† P  0.05 versus PBS-injected group and AxCANI-injected group.
‡ P  0.05 versus AxCANI-injected group.
§ P  0.05 versus PBS-injected group.
ANGIOSTATIC EFFECTS OF IL-4 GENE THERAPY IN AIA 2409
ment of RA patients (31). An imbalance of Th1/Th2
cytokines is likely to impact the chronic inflammation
associated with RA (32), with IL-4 playing a critical role
in the Th2 reaction and able to modulate the IL-1– and
TNF-mediated inflammatory responses (33,34).
Since treatment of RA requires therapeutic mea-
sures over a prolonged period, gene therapy has been
considered to be an interesting approach and also to
have advantages over conventional therapies that use
soluble receptors, antagonizing proteins, or blocking
antibodies. Indeed, gene therapy has been proven to be
useful in various animal models of arthritis (35), and
targeting angiogenesis using viral vectors, e.g., for en-
dostatin or soluble VEGF receptor 1, can efficiently
modify disease activity (36,37). However, cytokines, such
as IL-4, may provide a potential benefit by their ability
to also modify the immune response. We have previously
shown that IL-4 gene delivery into rat AIA joints
resulted in a decreased number of synovial tissue blood
vessels (12). However, it is unclear whether IL-4 affects
de novo growth of blood vessels in the arthritic joint.
Although it is possible that IL-4 has an indirect impact
on vessel growth via pro- and antiinflammatory cyto-
kines, it is conceivable that IL-4 treatment inhibits
angiogenesis independent of its antiinflammatory prop-
erties. In the present study we therefore evaluated the
Figure 5. Down-regulation of v integrins on endothelial cells (ECs) by AxCAIL-4 in rat AIA synovial tissue.
Immunohistochemical staining was performed for expression of the integrin chains v, 3, and 5 on lining cells
(LCs), mononuclear cells (MNCs), ECs, and smooth muscle cells (SMCs) in each group. A and B, The effects of
AxCAIL-4 on the integrin v chain (A) and 3 chain (B) were compared with those of PBS and AxCANI. C,
Representative images of staining for integrins v, 3, and 5 in rat AIA synovial tissue treated with AxCANI
or AxCAIL-4 (original magnification  200). Arrows indicate immunopositivity on ECs. n  number of animals.
See Figure 4 for other definitions.
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effect of IL-4 gene therapy on neovascularization in rat
AIA and identified possible pathways mediating this
process in vivo.
Angiogenesis starts very early in the course of
RA and may even precede the specific histopathologic
and clinical signs of inflammation (38). In the present
study, we show that blood vessel density in the synovium
is positively correlated with influx of inflammatory cells,
and that both parameters decrease following IL-4 gene
delivery (Figure 1). This is consistent with histologic
findings in human RA synovium, in which blood vessel
proliferation was found only in the presence of inflam-
mation (7,39). Of interest, in human RA, blood synovial
perfusion measured by Doppler ultrasound has also
been shown to be correlated with blood vessel density
and disease activity (40,41), whereas antiinflammatory
therapy in rat AIA is not necessarily associated with a
reduction in synovial vascularization (42), and therefore
might be causally unrelated.
Angiogenesis is initiated by dissolution of the
perivascular surrounding matrix as well as migration and
proliferation of ECs, with capillary sprouts joining to
form new blood vessels. The IL-4–mediated reduction of
synovial tissue blood vessels in rat AIA suggests its
participation in decreased angiogenesis. To examine this
possibility, we used rat AIA joint homogenates with and
without IL-4–producing adenovirus for in vitro and in
vivo angiogenesis assays.
First, we showed that rat AIA joint homogenates
induced EC chemotaxis in vitro (Figure 2A). Interest-
ingly, this effect was completely inhibited by AxCAIL-4,
suggesting that IL-4 gene delivery results in a net angio-
static effect in vivo. Of particular importance, AxCANI,
although promoting inflammation, had no impact on EC
migration. Thus, it might be that the antimigratory role
of IL-4 in ECs is unrelated to the antiinflammatory
effects.
Second, in an in vitro capillary morphogenesis
assay, we tested the role of IL-4 gene therapy on EC
differentiation (Figures 2B–D). Whereas joint homoge-
nates from the PBS- or AxCANI-treated groups induced
EC tube formation in vitro, this effect was not observed
with homogenates from AxCAIL-4–treated arthritic
rats. This suggests that IL-4 gene delivery in-
hibits EC differentiation, thereby resulting in less blood
vessel growth in vivo.
Third, to confirm previous data, we studied the
role of AxCAIL-4–treated rat AIA joint homogenates
on EC sprouting in the rat aortic ring assay (Figure 3), in
which both EC migration and differentiation can be
tested. Whereas significant sprouting occurred in re-
sponse to joint homogenates of the PBS and AxCANI
groups, IL-4 gene delivery resulted in significantly less
sprout formation, suggesting that IL-4 gene delivery
indeed promotes an antiangiogenic response.
Fourth, to determine if IL-4 can exert its angio-
static role in vivo, we tested the ability of rat AIA
homogenates to induce blood vessel penetration and
formation in a Matrigel plug in vivo angiogenesis assay.
In vivo blood vessel growth was significantly inhibited in
response to AxCAIL-4 homogenates compared with the
PBS-treated group and tended to be lower compared
with the AxCANI-treated group (Figure 4A). These
findings were corroborated by the observation of signif-
icantly lower hemoglobin levels in the AxCAIL-4–
treated group compared with PBS- or AxCANI-treated
rats, underscoring the angiostatic properties of IL-4 in
vivo (Figure 4B). In summary, IL-4 gene delivery was
able to inhibit important steps of neovascularization,
namely EC migration and differentiation, in vitro, as
well as blood vessel formation in vivo. Thus, IL-4 may be
directly or indirectly responsible for the reduction of
blood vessels in the synovium in the AxCAIL-4–treated
rats.
To elucidate the underlying mechanisms by which
IL-4 mediates its angiostatic role, we determined the
expression of select cytokines in the homogenates
(Table 1). IL-18, a proangiogenic cytokine in arthritis
(23), was significantly down-regulated in response to
IL-4 gene therapy in rat AIA. Similarly, expression of
the proangiogenic chemokine CXCL16 (29) was de-
creased by IL-4, while levels of the angiogenesis inhibi-
tor endostatin were up-regulated in the AxCAIL-4–
treated group compared with the group that received
AxCANI treatment. These effects on endostatin were
not present when the AxCAIL-4–treated group was
compared with the PBS-treated group. Conceivably,
the AxCAIL-4–mediated increase in endostatin levels
was masked by the effects of the adenovirus itself,
which significantly down-regulated joint endostatin ex-
pression. The data suggest that these proteins, at least
in part, mediate the IL-4–associated antiangiogenic ef-
fects in vivo.
Moreover, expression of LIX/CXCL5, the rat
homolog of the human proangiogenic chemokine
ENA-78/CXCL5, was strongly down-regulated by
AxCAIL-4. This is consistent with our previous data
showing that preventative blocking of increased
ENA-78, similar to the effects on protein levels in rat
AIA, modifies the severity of AIA (43). Similarly, levels
of CINC-1/CXCL1 were significantly lower in the
AxCAIL-4–treated group. The human homolog of
CINC-1, GRO/CXCL1, has been shown to promote
angiogenesis (44). Of interest, expression of IL-6 and
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IL-13 did not change following IL-4 gene delivery
when compared with AxCANI, suggesting that the
angiostatic effect of IL-4 in rat AIA is independent of
those cytokines. Moreover, AxCAIL-4 up-regulated
TGF in the in vivo setting of rat AIA. Indeed, TGF
is known to have a dual role in angiogenesis, either
promoting neovascularization or exhibiting angiostatic
effects (45,46). Since progression of angiogenesis de-
pends on the sum effects of pro- and antiangiogenic
factors (8), our data suggest that IL-4 shifts the balance
toward the angiostatic side. Of interest, the IL-4 effect
was more evident in comparison with AxCANI than
in comparison with PBS. This is consistent with previous
observations showing that adenoviral vectors have a
proinflammatory potential in vivo and can significantly
affect expression of various cytokines and growth factors
(12,15,47).
To study the functional relevance of our obser-
vations, we performed blocking studies for EC chemo-
taxis in response to AxCANI joint homogenates (Figure
4C). Neutralization of IL-18 and CXCL16 resulted in
significantly reduced EC migration, an effect similar to
that seen with IgG-treated AxCAIL-4 homogenates.
Thus, it is very likely that the IL-4–induced reduction of
CXCL16 and IL-18 contributes significantly to the an-
giostatic net effect of AxCAIL-4 homogenates. How-
ever, by blocking IL-4 with anti–IL-4 in the in vitro
morphogenesis assay, we showed that this cytokine is
also able to exert its angiostatic effects directly (Figure
4D), consistent with previous data (2,3). As expected,
blocking of already-low levels of IL-18 and CXCL16 in
the AxCAIL-4 homogenates did not affect EC tube
formation. This finding emphasizes the notion that IL-4
may exert its angiostatic effects both directly and indi-
rectly.
Surprisingly, in this study, IL-4 significantly in-
hibited neovascularization in the presence of high
VEGF levels. Although this seems to contradict the
paradigm of VEGF being a key player in angiogenesis,
there are plausible explanations for this observation.
1) The IL-4–induced angiostatic response is the net
balance of changes in levels of pro- and antiangiogenic
mediators in rat AIA synovial tissue. In fact, endostatin
has been shown to block VEGF-mediated signaling via
direct interaction with the VEGF receptor, Flk-1, in ECs
(48), and thus, if up-regulated, may neutralize the proan-
giogenic properties of VEGF. 2) IL-4 inhibits VEGF-
mediated neovascularization, a notion that is supported
by a recent study in which VEGF-induced EC chemo-
taxis and formation of tube-like structures by ECs in
vitro was significantly down-regulated by IL-4 (3), while
in the absence of VEGF, IL-4 enhanced EC tube
formation, suggesting an angiogenic activity of IL-4
under certain conditions. 3) IL-4 down-regulates the
expression of VEGF-specific receptors on ECs. IL-4
would thus reduce responses to VEGF, which possibly
represents a mechanism for negative feedback regula-
tion of angiogenesis, as has been demonstrated for v3
integrin (49).
Since v integrins are important regulators of
angiogenesis, we determined whether IL-4 gene therapy
could alter expression of integrins v3 and v5 on rat
AIA synovial tissue (Figure 5). Expression of the inte-
grin v chain on ECs was significantly down-regulated
by IL-4. In contrast, synovial expression of the integrin
5 chain was not significantly altered by IL-4 gene
delivery. These observations, together with evidence
that IL-4 regulates integrin v3 promoter activities
(50), suggest that IL-4 is able to exert its antiangiogenic
effects in rat AIA synovium via integrin v3, but not
v5.
In conclusion, we have shown in rat AIA that
IL-4 gene delivery results in antiangiogenic effects in
vitro and in vivo, the IL-4–induced antiangiogenic ef-
fects may be mediated directly or indirectly via alter-
ations in the expression of pro- and antiangiogenic
factors, and IL-4 may inhibit VEGF-mediated angio-
genesis and exert its antiangiogenic activity via integrin
v3. This study shows that IL-4 gene therapy is a useful
approach to the reduction of neovascularization in ar-
thritis. Since preventative treatment with IL-4 is not
feasible in humans, further studies are needed to deter-
mine how IL-4–associated angiostatic effects can be
directed to target treatment of inflammatory arthritis in
humans.
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